Skip to main content
Fig. 4 | Journal for ImmunoTherapy of Cancer

Fig. 4

From: Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial

Fig. 4

Soluble interleukin-2 receptor-α in patients treated or untreated with denileukin diftitox. Blood was drawn before and after subjects were treated on the trial. Serum was aliquoted and stored at -80 °C until analysis. Soluble interleukin-2 receptor (soluble CD25) levels were analyzed by ELISA. Student t-test (assuming different variance in each group) was used to determine whether there was a statistical difference between the pre and post samples in each cohort and between the two cohorts

Back to article page